Close Menu

NEW YORK – Beckman Coulter announced Monday its Access SARS-CoV-2 IgG assay received Emergency Use Authorization from the US Food and Drug Administration.

The serology test targets IgG antibodies that recognize the receptor binding domain of the spike protein that SARS-CoV-2 uses to bind to a human cell receptor. These antibodies have the potential to be neutralizing, the company said. The test has confirmed 100 percent sensitivity and nearly 100 percent specificity, the firm added. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.